SemBioSys Genetics Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,098,383, titled "Methods for the protection of multimeric immunoglobulins and related compositions." It covers the production of antibodies in association with oilbodies.

TargeGen Inc., of San Diego, received a notice of allowance for a patent covering TG100-115, a selective P13 kinase inhibitor that has demonstrated an ability to suppress vascular leakage and inflammation, and related compounds.

Targeted Genetics Corp., of Seattle, was issued U.S. Patent No. 7,105,345, titled "Adeno-Associated Virus Serotype 1 Nucleic Acid Sequences, Vectors and Host Cells Containing Same." It covers compositions of AAV vectors that encode capsid proteins derived from AAV serotype 1 and host cells into which such vectors are introduced. The company also received U.S. Patent No. 7,122,335, describing an approach for improving the efficiency with which AAV vectors deliver genes to target cells.

Vical Inc., of San Diego, was issued U.S. Patent No. 7,105,574, covering both the Vaxfectin adjuvant and its use with conventional vaccines against infectious diseases and cancer.